首页 | 本学科首页   官方微博 | 高级检索  
     


De novo mutations of GCK,HNF1A and HNF4A may be more frequent in MODY than previously assumed
Authors:Juraj Stanik  Petra Dusatkova  Ondrej Cinek  Lucia Valentinova  Miroslava Huckova  Martina Skopkova  Lenka Dusatkova  Daniela Stanikova  Mikulas Pura  Iwar Klimes  Jan Lebl  Daniela Gasperikova  Stepanka Pruhova
Affiliation:1. DIABGENE Laboratory, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Vlarska 3, SK-833 06, Bratislava, Slovakia
2. First Department of Pediatrics, Medical Faculty of Comenius University, Bratislava, Slovakia
3. Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and University Hospital Motol, Prague, Czech Republic
4. National Institute of Endocrinology and Diabetology, Lubochna, Slovakia
5. Centre for Molecular Medicine, Slovak Academy of Sciences, Bratislava, Slovakia
Abstract:

Aims/hypothesis

MODY is mainly characterised by an early onset of diabetes and a positive family history of diabetes with an autosomal dominant mode of inheritance. However, de novo mutations have been reported anecdotally. The aim of this study was to systematically revisit a large collection of MODY patients to determine the minimum prevalence of de novo mutations in the most prevalent MODY genes (i.e. GCK, HNF1A, HNF4A).

Methods

Analysis of 922 patients from two national MODY centres (Slovakia and the Czech Republic) identified 150 probands (16%) who came from pedigrees that did not fulfil the criterion of two generations with diabetes but did fulfil the remaining criteria. The GCK, HNF1A and HNF4A genes were analysed by direct sequencing.

Results

Mutations in GCK, HNF1A or HNF4A genes were detected in 58 of 150 individuals. Parents of 28 probands were unavailable for further analysis, and in 19 probands the mutation was inherited from an asymptomatic parent. In 11 probands the mutations arose de novo.

Conclusions/interpretation

In our cohort of MODY patients from two national centres the de novo mutations in GCK, HNF1A and HNF4A were present in 7.3% of the 150 families without a history of diabetes and 1.2% of all of the referrals for MODY testing. This is the largest collection of de novo MODY mutations to date, and our findings indicate a much higher frequency of de novo mutations than previously assumed. Therefore, genetic testing of MODY could be considered for carefully selected individuals without a family history of diabetes.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号